DK1778673T3 - Nye hydantoin-derivater til behandling af obstruktive luftvejssygdomme - Google Patents

Nye hydantoin-derivater til behandling af obstruktive luftvejssygdomme

Info

Publication number
DK1778673T3
DK1778673T3 DK05756403.1T DK05756403T DK1778673T3 DK 1778673 T3 DK1778673 T3 DK 1778673T3 DK 05756403 T DK05756403 T DK 05756403T DK 1778673 T3 DK1778673 T3 DK 1778673T3
Authority
DK
Denmark
Prior art keywords
treatment
obstructive airway
airway diseases
hydantoin derivatives
new hydantoin
Prior art date
Application number
DK05756403.1T
Other languages
Danish (da)
English (en)
Inventor
Balint Gabos
Lena Ripa
Kristina Stenvall
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Application granted granted Critical
Publication of DK1778673T3 publication Critical patent/DK1778673T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pulmonology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
DK05756403.1T 2004-07-05 2005-07-04 Nye hydantoin-derivater til behandling af obstruktive luftvejssygdomme DK1778673T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE0401762A SE0401762D0 (sv) 2004-07-05 2004-07-05 Novel compounds
PCT/SE2005/001092 WO2006004532A1 (en) 2004-07-05 2005-07-04 Novel hydantoin derivatives for the treatment of obstructive airway diseases

Publications (1)

Publication Number Publication Date
DK1778673T3 true DK1778673T3 (da) 2010-03-01

Family

ID=32768773

Family Applications (1)

Application Number Title Priority Date Filing Date
DK05756403.1T DK1778673T3 (da) 2004-07-05 2005-07-04 Nye hydantoin-derivater til behandling af obstruktive luftvejssygdomme

Country Status (32)

Country Link
US (1) US7989620B2 (enExample)
EP (1) EP1778673B1 (enExample)
JP (1) JP4390833B2 (enExample)
KR (1) KR101222736B1 (enExample)
CN (1) CN100543024C (enExample)
AR (1) AR049578A1 (enExample)
AT (1) ATE448219T1 (enExample)
AU (1) AU2005260142B2 (enExample)
BR (1) BRPI0512974A (enExample)
CA (1) CA2569716C (enExample)
CY (1) CY1109728T1 (enExample)
DE (1) DE602005017636D1 (enExample)
DK (1) DK1778673T3 (enExample)
ES (1) ES2335424T3 (enExample)
HR (1) HRP20100020T1 (enExample)
IL (1) IL179906A (enExample)
MX (1) MXPA06014661A (enExample)
MY (1) MY145613A (enExample)
NO (1) NO20070576L (enExample)
NZ (1) NZ552101A (enExample)
PL (1) PL1778673T3 (enExample)
PT (1) PT1778673E (enExample)
RS (1) RS51280B (enExample)
RU (1) RU2386629C2 (enExample)
SA (1) SA05260192B1 (enExample)
SE (1) SE0401762D0 (enExample)
SI (1) SI1778673T1 (enExample)
TW (1) TWI353985B (enExample)
UA (1) UA86977C2 (enExample)
UY (1) UY29002A1 (enExample)
WO (1) WO2006004532A1 (enExample)
ZA (1) ZA200610698B (enExample)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE0100902D0 (sv) 2001-03-15 2001-03-15 Astrazeneca Ab Compounds
SE0202539D0 (sv) 2002-08-27 2002-08-27 Astrazeneca Ab Compounds
SE0401762D0 (sv) 2004-07-05 2004-07-05 Astrazeneca Ab Novel compounds
US7648992B2 (en) 2004-07-05 2010-01-19 Astrazeneca Ab Hydantoin derivatives for the treatment of obstructive airway diseases
SE0401763D0 (sv) * 2004-07-05 2004-07-05 Astrazeneca Ab Compounds
US7776869B2 (en) * 2004-10-18 2010-08-17 Amgen Inc. Heteroaryl-substituted alkyne compounds and method of use
SE0403085D0 (sv) 2004-12-17 2004-12-17 Astrazeneca Ab Novel componds
SE0403086D0 (sv) 2004-12-17 2004-12-17 Astrazeneca Ab Compounds
TW200740769A (en) 2006-03-16 2007-11-01 Astrazeneca Ab Novel process
TW200831488A (en) * 2006-11-29 2008-08-01 Astrazeneca Ab Novel compounds
GB0702456D0 (en) 2007-02-08 2007-03-21 Astrazeneca Ab New combination
WO2009007747A2 (en) * 2007-07-11 2009-01-15 Astrazeneca Ab Hydantoin derivatives used as mmp12 inhibitors
GB0913345D0 (en) 2009-07-31 2009-09-16 Astrazeneca Ab New combination 802
WO2011061527A1 (en) 2009-11-17 2011-05-26 Astrazeneca Ab Combinations comprising a glucocorticoid receptor modulator for the treatment of respiratory diseases
WO2011073662A1 (en) 2009-12-17 2011-06-23 Astrazeneca Ab Combination of a benzoxazinone and a further agent for treating respiratory diseases
GB201021979D0 (en) 2010-12-23 2011-02-02 Astrazeneca Ab New compound
GB201021992D0 (en) 2010-12-23 2011-02-02 Astrazeneca Ab Compound
EP2907512A1 (en) 2014-02-14 2015-08-19 Commissariat A L'energie Atomique Et Aux Energies Alternatives Inhibitors of MMP-12 as antiviral Agents
RU2555341C1 (ru) * 2014-04-29 2015-07-10 Федеральное бюджетное учреждение науки "Федеральный научный центр медико-профилактических технологий управления рисками здоровью населения" (ФБУН "ФНЦ медико-профилактических технологий управления рисками здоровью населения") Способ профилактики развития у детей старше 5 лет неконтролируемых форм бронхиальной астмы, обусловленных воздействием марганца и ванадия
MX2017009843A (es) 2015-01-30 2017-11-02 Basf Se Fenilpirimidinas herbicidas.
WO2018019552A1 (en) 2016-07-25 2018-02-01 Basf Se Herbicidal pyrimidine compounds
BR112018076642A2 (pt) 2016-07-25 2019-03-26 Basf Se compostos de pirimidina, compostos de pirimidina de fórmula e seu uso, composições herbicidas, método de controle de vegetação indesejada e uso das composições
EP3638033A1 (en) 2017-06-14 2020-04-22 Basf Se Herbicidal pyrimidine compounds
WO2019121408A1 (en) 2017-12-20 2019-06-27 Basf Se Herbicidal pyrimidine compounds
IL279641B2 (en) 2018-07-16 2024-04-01 Heparegenix Gmbh Protein kinase inhibitors for promoting liver regeneration or reducing or preventing hepatocyte death
ES2959616T3 (es) 2018-09-19 2024-02-27 Bayer Ag Hidrazidas de fenilpirimidina sustituidas con efecto herbicida
CN116033902A (zh) * 2020-06-26 2023-04-28 伯明翰大学 治疗脊髓损伤或相关神经组织损伤的方法
GB202403774D0 (en) 2024-03-15 2024-05-01 Univ Sheffield Treatment of stroke

Family Cites Families (74)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2327890A (en) * 1940-04-17 1943-08-24 Parke Davis & Co Substituted phenoxyalkyl ethers
US2745875A (en) * 1953-06-30 1956-05-15 Hoechst Ag Preparation of nu-acylamino-phenylpropane diols
US3452040A (en) * 1966-01-05 1969-06-24 American Home Prod 5,5-disubstituted hydantoins
US3529019A (en) * 1968-04-23 1970-09-15 Colgate Palmolive Co Alkylaryloxy alanines
US3849574A (en) * 1971-05-24 1974-11-19 Colgate Palmolive Co Alpha-substituted-beta-arylthioalkyl amino-acids,for increasing heart rate
US4315031A (en) * 1977-09-01 1982-02-09 Science Union Et Cie Thiosubstituted amino acids
GB1601310A (en) * 1978-05-23 1981-10-28 Lilly Industries Ltd Aryl hydantoins
JPS6172762A (ja) 1984-09-17 1986-04-14 Kanegafuchi Chem Ind Co Ltd 光学活性ヒダントイン類の製造法
JPS61212292A (ja) * 1985-03-19 1986-09-20 Mitsui Toatsu Chem Inc Ｄ−α−アミノ酸の製造方法
CA1325222C (en) 1985-08-23 1993-12-14 Lederle (Japan), Ltd. Process for producing 4-biphenylylacetic acid
GB8618559D0 (en) 1986-07-30 1986-09-10 Genetics Int Inc Rhodococcus bacterium
US4983771A (en) * 1989-09-18 1991-01-08 Hexcel Corporation Method for resolution of D,L-alpha-phenethylamine with D(-)mandelic acid
NL9000386A (nl) 1990-02-16 1991-09-16 Stamicarbon Werkwijze voor de bereiding van optisch aktief aminozuuramide.
DK161690D0 (da) 1990-07-05 1990-07-05 Novo Nordisk As Fremgangsmaade til fremstilling af enantiomere forbindelser
IL99957A0 (en) 1990-11-13 1992-08-18 Merck & Co Inc Piperidinylcamphorsulfonyl oxytocin antagonists and pharmaceutical compositions containing them
PH31245A (en) * 1991-10-30 1998-06-18 Janssen Pharmaceutica Nv 1,3-Dihydro-2H-imidazoÄ4,5-BÜ-quinolin-2-one derivatives.
US5308853A (en) * 1991-12-20 1994-05-03 Warner-Lambert Company Substituted-5-methylidene hydantoins with AT1 receptor antagonist properties
US5246943A (en) * 1992-05-19 1993-09-21 Warner-Lambert Company Substituted 1,2,3,4-tetahydroisoquinolines with angiotensin II receptor antagonist properties
NL9201230A (nl) 1992-07-09 1994-02-01 Dsm Nv Werkwijze voor de bereiding van optisch aktief methionineamide.
EP0640594A1 (en) 1993-08-23 1995-03-01 Fujirebio Inc. Hydantoin derivative as metalloprotease inhibitor
JPH09505310A (ja) 1993-11-16 1997-05-27 メルク エンド カンパニー インコーポレーテッド ピペリジンショウノウスルホニルオキシトシン拮抗剤
EP0709375B1 (en) 1994-10-25 2005-05-18 AstraZeneca AB Therapeutic heterocycles
ZA96211B (en) 1995-01-12 1996-07-26 Teva Pharma Compositions containing and methods of using 1- aminoindan and derivatives thereof and process for preparing optically active 1-aminoindan derivatives
US5863949A (en) 1995-03-08 1999-01-26 Pfizer Inc Arylsulfonylamino hydroxamic acid derivatives
US6166041A (en) * 1995-10-11 2000-12-26 Euro-Celtique, S.A. 2-heteroaryl and 2-heterocyclic benzoxazoles as PDE IV inhibitors for the treatment of asthma
KR19990067687A (ko) * 1995-11-22 1999-08-25 마르크 젠너 이미다졸 치환체를 갖는 메캅토알킬펩티딜 화합물 및 매트릭스금속단백질 가수분해 효소의 억제제 및/또는 종양 괴사 인자로서의 용도
GB9616643D0 (en) * 1996-08-08 1996-09-25 Chiroscience Ltd Compounds
US5919790A (en) * 1996-10-11 1999-07-06 Warner-Lambert Company Hydroxamate inhibitors of interleukin-1β converting enzyme
ATE212619T1 (de) * 1996-10-22 2002-02-15 Upjohn Co Alpha-amino sulfonyl hydroxamsäure als matrix metalloproteinase inhibitoren
EP0983239A1 (en) 1997-05-06 2000-03-08 Novo Nordisk A/S Novel heterocyclic compounds
PT877019E (pt) * 1997-05-09 2002-05-31 Hoechst Ag Acidos diaminocarboxilicos substituidos
NZ501166A (en) 1997-07-31 2001-12-21 Abbott Lab Reverse hydroxamate-containing compounds and their use as inhibitors of matrix metalloproteinases
TW514634B (en) 1997-10-14 2002-12-21 Lilly Co Eli Process to make chiral compounds
BR9814147A (pt) 1997-11-12 2000-10-03 Darwin Discovery Ltd "derivados de ácido carboxìlico e hidroxâmico tendo atividade inibitória de mmp e tnf"
SK11692000A3 (sk) * 1998-02-04 2001-02-12 Novartis Ag Sulfonylaminoderiváty, ktoré inhibujú metaloproteinázy degradujúce matricu, spôsob ich prípravy a farmaceutická kompozícia, ktorá ich obsahuje
US6329418B1 (en) * 1998-04-14 2001-12-11 The Procter & Gamble Company Substituted pyrrolidine hydroxamate metalloprotease inhibitors
WO1999058528A1 (en) 1998-05-14 1999-11-18 Bristol-Myers Squibb Pharma Company. Substituted aryl hydroxamic acids as metalloproteinase inhibitors
EP1084106A1 (en) 1998-06-03 2001-03-21 GPI NIL Holdings, Inc. N-linked sulfonamides of heterocyclic carboxylic acids or carboxylic acid isosteres
WO1999065867A1 (en) * 1998-06-17 1999-12-23 Du Pont Pharmaceuticals Company Cyclic hydroxamic acids as metalloproteinase inhibitors
FR2782082B3 (fr) * 1998-08-05 2000-09-22 Sanofi Sa Formes cristallines de (r)-(+)-n-[[3-[1-benzoyl-3-(3,4- dichlorophenyl)piperidin-3-yl]prop-1-yl]-4-phenylpiperidin-4 -yl]-n-methylacetamide (osanetant) et procede pour la preparation dudit compose
US6339101B1 (en) * 1998-08-14 2002-01-15 Gpi Nil Holdings, Inc. N-linked sulfonamides of N-heterocyclic carboxylic acids or isosteres for vision and memory disorders
DE69907238T2 (de) 1998-10-07 2003-11-06 Yazaki Corp., Tokio/Tokyo Sol-gel verfahren unter verwendung poröser formen
DE69915004T2 (de) * 1998-11-05 2004-09-09 Pfizer Products Inc., Groton 5-Oxo-pyrrolidine-2-Carbonsäure-Hydroxamidderivate
US6340691B1 (en) * 1999-01-27 2002-01-22 American Cyanamid Company Alkynyl containing hydroxamic acid compounds as matrix metalloproteinase and tace inhibitors
CZ20012714A3 (cs) 1999-01-28 2002-08-14 Chugai Seiyaku Kabushiki Kaisha Substituované deriváty fenetylaminu
US20020006920A1 (en) * 1999-07-22 2002-01-17 Robinson Ralph Pelton Arylsulfonylamino hydroxamic acid derivatives
EP1078923B1 (en) * 1999-08-02 2006-03-08 F. Hoffmann-La Roche Ag Process for the preparation of benzothiophene derivatives
SK1812002A3 (en) * 1999-08-12 2003-02-04 Pharmacia Italia Spa 3(5)-Amino-pyrazole derivatives, process for their preparation and their use as antitumor agents
US6283379B1 (en) * 2000-02-14 2001-09-04 Kic Thermal Profiling Method for correlating processor and part temperatures using an air temperature sensor for a conveyorized thermal processor
PL365909A1 (en) * 2000-02-21 2005-01-10 Astrazeneca Ab Piperidine- and piperazine substituted n-hydroxyformamides as inhibitors of metalloproteinases
US6525202B2 (en) * 2000-07-17 2003-02-25 Wyeth Cyclic amine phenyl beta-3 adrenergic receptor agonists
US20020065219A1 (en) * 2000-08-15 2002-05-30 Naidu B. Narasimhulu Water soluble thiazolyl peptide derivatives
US20020091107A1 (en) * 2000-09-08 2002-07-11 Madar David J. Oxazolidinone antibacterial agents
EP1191024A1 (en) 2000-09-22 2002-03-27 Harald Tschesche Thiadiazines and their use as inhibitors of metalloproteinases
SE0100902D0 (sv) * 2001-03-15 2001-03-15 Astrazeneca Ab Compounds
SE0100903D0 (sv) * 2001-03-15 2001-03-15 Astrazeneca Ab Compounds
JP2004527511A (ja) * 2001-03-15 2004-09-09 アストラゼネカ・アクチエボラーグ メタロプロテイナーゼ阻害剤
JP2004535411A (ja) * 2001-05-25 2004-11-25 ブリストルーマイヤーズ スクイブ カンパニー マトリックスメタロプロテナーゼ及び／またはＴＮＦ−α転換酵素（ＴＡＣＥ）の阻害剤としてのヒダントイン及び関連複素環化合物
GB0114004D0 (en) * 2001-06-08 2001-08-01 Glaxo Group Ltd Chemical compounds
SE0103710D0 (sv) * 2001-11-07 2001-11-07 Astrazeneca Ab Compounds
EP2287152B1 (en) 2002-06-05 2015-01-14 Kaneka Corporation Process for producing optically active alpha-methylcysteine derivative
SE0202539D0 (sv) * 2002-08-27 2002-08-27 Astrazeneca Ab Compounds
GB0221250D0 (en) 2002-09-13 2002-10-23 Astrazeneca Ab Compounds
GB0221246D0 (en) * 2002-09-13 2002-10-23 Astrazeneca Ab Compounds
US20040266832A1 (en) * 2003-06-26 2004-12-30 Li Zheng J. Crystal forms of 2-(3-difluoromethyl-5-phenyl-pyrazol-1-yl)-5-methanesulfonyl pyridine
TWI220073B (en) * 2003-07-24 2004-08-01 Au Optronics Corp Method for manufacturing polysilicon film
SE0401762D0 (sv) 2004-07-05 2004-07-05 Astrazeneca Ab Novel compounds
SE0401763D0 (sv) * 2004-07-05 2004-07-05 Astrazeneca Ab Compounds
US7648992B2 (en) * 2004-07-05 2010-01-19 Astrazeneca Ab Hydantoin derivatives for the treatment of obstructive airway diseases
SE0403085D0 (sv) * 2004-12-17 2004-12-17 Astrazeneca Ab Novel componds
SE0403086D0 (sv) * 2004-12-17 2004-12-17 Astrazeneca Ab Compounds
TW200800954A (en) 2006-03-16 2008-01-01 Astrazeneca Ab Novel crystal modifications
TW200740769A (en) * 2006-03-16 2007-11-01 Astrazeneca Ab Novel process
TW200831488A (en) * 2006-11-29 2008-08-01 Astrazeneca Ab Novel compounds

Also Published As

Publication number Publication date
DE602005017636D1 (de) 2009-12-24
AU2005260142B2 (en) 2008-08-28
TWI353985B (en) 2011-12-11
NZ552101A (en) 2010-11-26
IL179906A (en) 2011-11-30
SI1778673T1 (sl) 2010-02-26
CY1109728T1 (el) 2014-09-10
CN1980914A (zh) 2007-06-13
CN100543024C (zh) 2009-09-23
CA2569716A1 (en) 2006-01-12
BRPI0512974A (pt) 2008-04-22
ATE448219T1 (de) 2009-11-15
KR20070041495A (ko) 2007-04-18
EP1778673A1 (en) 2007-05-02
US20100144771A1 (en) 2010-06-10
RU2386629C2 (ru) 2010-04-20
HK1102814A1 (en) 2007-12-07
NO20070576L (no) 2007-04-10
HRP20100020T1 (hr) 2010-02-28
MY145613A (en) 2012-03-15
IL179906A0 (en) 2007-05-15
RS51280B (sr) 2010-12-31
AR049578A1 (es) 2006-08-16
PT1778673E (pt) 2010-01-13
TW200616995A (en) 2006-06-01
EP1778673B1 (en) 2009-11-11
AU2005260142A1 (en) 2006-01-12
US7989620B2 (en) 2011-08-02
SE0401762D0 (sv) 2004-07-05
ZA200610698B (en) 2008-06-25
RU2007101236A (ru) 2008-08-10
PL1778673T3 (pl) 2010-03-31
UA86977C2 (ru) 2009-06-10
JP2008505171A (ja) 2008-02-21
JP4390833B2 (ja) 2009-12-24
KR101222736B1 (ko) 2013-01-15
UY29002A1 (es) 2006-02-24
ES2335424T3 (es) 2010-03-26
MXPA06014661A (es) 2007-02-12
SA05260192B1 (ar) 2009-02-07
CA2569716C (en) 2013-02-19
WO2006004532A1 (en) 2006-01-12

Similar Documents

Publication Publication Date Title
DK1778673T3 (da) Nye hydantoin-derivater til behandling af obstruktive luftvejssygdomme
DK3456707T3 (da) 4-(p-quinonyl)-2-hydroxybutanamidderivater til behandling af mitokondriesygdomme
DK1656347T3 (da) Substituerede indolderivater til farmaceutisk sammensætning til behandling af luftvejssygdomme
DK1937633T3 (da) Biphenyloxyeddikesyrederivater til behandling af respiratoriske sygdomme
DK1471057T3 (da) Pyrimidinyleddikesyrederivater, der er egnede til behandlingen af sygdomme medieret af CRTH2
DK1708992T3 (da) Sulfonamidderivater til behandling af sygdomme
DK2019683T4 (da) Indgivelse af vækstfaktorer til behandling af CNS-lidelser
DK1817282T3 (da) Til behandling af respiratoriske sygdomme egnede phenoxy derivater
DK1562603T3 (da) Nye l gemidler til behandling af kronisk obstruktive lungesydomme
DK2463283T3 (da) Kondenserede heterocykliske phenylamidoforbindelser til forebyggelse og behandling af glucokinase-medierede sygdomme
DK1556342T3 (da) Phenethanolaminderivat til behandling af respiratoriske sygdomme
DK1874781T3 (da) Dihydrothienopyrimidiner til behandling af inflammatoriske sygdomme
CY2016015I2 (el) Αζετιδινες ως αναστολεις μεκ για τη θεραπευτικη αγωγη πολλαπλασιαστικων ασθενειων
HUS1500058I1 (hu) Benzoxazint tartalmazó gyógyszer-kombináció légúti betegségek kezelésére
IL180736A0 (en) Hydantoin derivatives for the treatment of inflammatory disorders
DK1812110T3 (da) Apparat til behandling af dermatologiske lidelser
DK2056842T3 (da) Modificeret galactosylceramid til behandling af cancerøse sygdomme
DK1830850T3 (da) Quinolin-derivater til behandling af latent tuberkulose
DK2285808T3 (da) Spiroindolderivater til behandling af parasitsygdomme
DK1708991T3 (da) Sulfonamid derivater til behandling af sygdomme
DK1890684T3 (da) Behandling af søvn/vågenhedsforstyrrelser
DK1948615T3 (da) Til behandling af gynækologiske sygdomme egnede pyrazolderivater
DK2041093T3 (da) Til behandling af GPR38-receptor medierede sygdomme anvendelige piperazinylderivativer
DK1701944T3 (da) 2-(amino-substituerede)-4-aryl-pyramidiner og relaterede forbindelser til behandling af inflammationssygdomme
DK2117565T3 (da) Anvendelse af chitosaner til behandlingen af negleinflammatoriske sygdomme